Latest / Decera Clinical Education Oncology Podcast
Improving Outcomes for Patients With CML With TKIs: FAQ Podcast
In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:
Frontline Management of Chronic-Phase CML
Selection of TKI Based on Goal of Treatment-Free Remission
Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
Changing TKIs due to CML Progression: Second-line Therapy and Future Options
Presenters:
Prof. Dr. med Tim Henrik Brümmendorf
Head
Department of Hematology…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.